scPhar­ma­cu­ti­cals rais­es $45M B round; Strug­gling Ni­valis and Acu­ra take stock of “strate­gic al­ter­na­tives”

• Lex­ing­ton, MA-based scPhar­ma­ceu­ti­cals, which is tak­ing gener­ic drugs and re­for­mu­lat­ing them for sub­cu­ta­neous in­jec­tion, has raised $45.6 mil­lion in its Se­ries B round. The round was co-led by Or­biMed and a whol­ly-owned sub­sidiary of Sun Phar­ma­ceu­ti­cal In­dus­tries, Sun Phar­ma. Ex­ist­ing in­vestors 5AM Ven­tures and Lund­beck­fond Ven­tures par­tic­i­pat­ed in the fi­nanc­ing.

• A month af­ter Ni­valis $NVLS saw its shares crater af­ter its lead pro­gram flunked a mid-stage tri­al, the biotech is look­ing at its strate­gic al­ter­na­tives while cut­ting back on costs. Ni­valis says it will com­plete its on­go­ing SNO-7 tri­al of cavoson­stat in pa­tients with CF who are cur­rent­ly tak­ing Ka­ly­de­co (iva­caftor), which is ex­pect­ed to be com­plet­ed in the first quar­ter of 2017.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.